SUBSCRIBE: Print / eNewsletter
Immunotherapy Combination Active in Advanced Melanoma
Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.
Pembrolizumab Improved Survival vs Ipilimumab in Advanced Melanoma
Treatment with pembrolizumab resulted in an estimated 6-month PFS rate that was almost double that of treatment with ipilimumab in advanced melanoma patients.
AACR: Insulin Signaling and Cancer Development, Progression
Ahead of the 2015 AACR Annual Meeting we discuss how insulin resistance relates to current cancer therapies.